Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation

AIM: This study aimed to evaluate the safety and efficacy profile of low-dose tocilizumab (TCZ), to prevent disease progression, subcutaneously administered to patients with moderate COVID-19 pneumonia and hyperinflammation. METHODS: Clinical characteristics and outcomes were retrospectively analyse...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Infect Dis
Autori principali: Potere, Nicola, Di Nisio, Marcello, Rizzo, Giulia, La Vella, Matteo, Polilli, Ennio, Agostinone, Adriana, Spacone, Antonella, Di Carlo, Silvio, Costantini, Alberto, Abbate, Antonio, Porreca, Ettore, Parruti, Giustino
Natura: Artigo
Lingua:Inglês
Pubblicazione: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Soggetti:
Short Communication
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7406468/
https://ncbi.nlm.nih.gov/pubmed/32768701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijid.2020.07.078
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi